Search research articles
Contact Us
Filters
Showing results (11-20 of 45) with videos related to
Page
of 5
Sort By:
Leukemia & Lymphoma
|
May 11, 2019
Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
Jacob D Soumerai, Matthew S Davids, Lillian Werner, et al.
Leukemia & Lymphoma
|
June 6, 2013
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease
Jacob D Soumerai, Matthew D Hellmann, Yang Feng, et al.
The Lancet. Oncology
|
July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
John M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Leukemia & Lymphoma
|
November 9, 2018
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials
Jacob D Soumerai, Ai Ni, Guan Xing, et al.
Blood Cancer Journal
|
November 1, 2022
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
Kevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, et al.
American Journal of Hematology
|
July 16, 2016
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome
Jacob R Bledsoe, Robert A Redd, Robert P Hasserjian, et al.
Blood
|
October 26, 2021
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Tanya Siddiqi, Jacob D Soumerai, Kathleen A Dorritie, et al.
Blood
|
November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
Steven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
Leukemia & Lymphoma
|
December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.
Blood Advances
|
June 21, 2024
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence
Jacob D Soumerai, Zaid Yousif, Thais Gift, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 45) with videos related to
Sort By:
Page
of 5
Leukemia & Lymphoma
|
May 11, 2019
Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
Jacob D Soumerai, Matthew S Davids, Lillian Werner, et al.
Leukemia & Lymphoma
|
June 6, 2013
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease
Jacob D Soumerai, Matthew D Hellmann, Yang Feng, et al.
The Lancet. Oncology
|
July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
John M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.
Leukemia & Lymphoma
|
November 9, 2018
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials
Jacob D Soumerai, Ai Ni, Guan Xing, et al.
Blood Cancer Journal
|
November 1, 2022
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
Kevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, et al.
American Journal of Hematology
|
July 16, 2016
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome
Jacob R Bledsoe, Robert A Redd, Robert P Hasserjian, et al.
Blood
|
October 26, 2021
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Tanya Siddiqi, Jacob D Soumerai, Kathleen A Dorritie, et al.
Blood
|
November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
Steven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
Leukemia & Lymphoma
|
December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.
Blood Advances
|
June 21, 2024
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence
Jacob D Soumerai, Zaid Yousif, Thais Gift, et al.
Page
of 5